AQR Capital Management LLC Invests $113,000 in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

AQR Capital Management LLC purchased a new position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 15,626 shares of the company’s stock, valued at approximately $113,000.

Other institutional investors have also recently bought and sold shares of the company. Thoroughbred Financial Services LLC acquired a new stake in Larimar Therapeutics during the second quarter worth $94,000. EntryPoint Capital LLC acquired a new stake in Larimar Therapeutics during the first quarter worth $106,000. Virtu Financial LLC acquired a new stake in Larimar Therapeutics during the first quarter worth $133,000. Ballentine Partners LLC acquired a new stake in Larimar Therapeutics during the second quarter worth $137,000. Finally, Squarepoint Ops LLC boosted its stake in Larimar Therapeutics by 174.6% during the second quarter. Squarepoint Ops LLC now owns 29,858 shares of the company’s stock worth $216,000 after buying an additional 69,858 shares in the last quarter. Institutional investors and hedge funds own 91.92% of the company’s stock.

Larimar Therapeutics Stock Down 1.1 %

Larimar Therapeutics stock opened at $7.76 on Friday. The stock has a 50-day simple moving average of $7.32 and a 200 day simple moving average of $7.76. Larimar Therapeutics, Inc. has a 12-month low of $2.18 and a 12-month high of $13.68. The stock has a market capitalization of $495.10 million, a price-to-earnings ratio of -8.00 and a beta of 0.98.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). As a group, sell-side analysts anticipate that Larimar Therapeutics, Inc. will post -1.39 EPS for the current year.

Analysts Set New Price Targets

LRMR has been the topic of a number of recent research reports. Baird R W upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 4th. Robert W. Baird started coverage on Larimar Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $16.00 price objective for the company. Oppenheimer started coverage on Larimar Therapeutics in a report on Wednesday. They set an “outperform” rating and a $26.00 price objective for the company. HC Wainwright started coverage on Larimar Therapeutics in a report on Wednesday, October 2nd. They set a “buy” rating and a $15.00 price objective for the company. Finally, Wedbush started coverage on Larimar Therapeutics in a report on Thursday, October 3rd. They set an “outperform” rating and a $22.00 price objective for the company. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $20.43.

Larimar Therapeutics Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.